Stockscreener 앱 받기
127.63
1.41%
-1.82
시장 영업 전:
127.32
-0.31
-0.24%
Abbott Laboratories 주식(ABT)의 최신 뉴스
Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength - Benzinga
These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds - Seeking Alpha
Abbott cuts top end of 2025 guidance as tariff threat looms - Modern Healthcare
UBS reiterates Buy rating on Abbott Labs stock amid sustainable MedTech growth - Investing.com India
Barclays Adjusts Abbott Laboratories Price Target to $162 From $159 - MarketScreener
Abbott Labs Q3 2025: Medical Devices Drive 6.9% Sales Growth - Dallas Express
Abbott Labs stock rating reiterated at Buy by Benchmark on strong device sales - Investing.com
Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on Abbott Laboratories to $149 From $145, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Abbott Laboratories Price Target to $150 From $145, Maintains Outperform Rating - MarketScreener
Raymond James Adjusts Abbott Laboratories Price Target to $146 From $141, Maintains Outperform Rating - MarketScreener
Jefferies Adjusts Abbott Laboratories Price Target to $149 From $145, Maintains Buy Rating - MarketScreener
Abbott Labs stock rating reiterated at Outperform by RBC despite mixed results - Investing.com India
Abbott’s strong Q3 medtech performance offset by diagnostic weakness - Medical Device Network
Abbott Labs stock price target raised to $146 by Wells Fargo on Medtech strength - Investing.com India
Jefferies raises Abbott Labs stock price target to $146 on medical device growth - Investing.com
Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating - TipRanks
ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook - The Globe and Mail
Abbott (ABT) Profit Margin Surge Challenges Bearish Narratives Despite Earnings Decline Forecast - simplywall.st
Abbott Laboratories Reports Strong Q3 2025 Earnings - TipRanks
Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast - Yahoo
Abbott Laboratories Keeps Its Cool Despite A Slight Sales Miss - Finimize
Abbott Laboratories’ Earnings Call Highlights Strong Growth - TipRanks
Strong Performance and Future Potential: Buy Rating for Abbott Laboratories - TipRanks
Why Abbott Laboratories (ABT) Stock Is Down Today - The Globe and Mail
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ... - Yahoo Finance
Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Benzinga
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Abbott narrows outlook, Australian stocks react to US-China trade - Yahoo Finance
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025 - GuruFocus
Abbott CEO: ‘We’re right on time’ to the PFA party - MedTech Dive
Abbott Q3 results come up shy of sales forecast, Medical Device sales grow 15% - MassDevice
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside - GuruFocus
Is it Time to Buy the Abbott Labs Dip? - TheStreet Pro
Abbott Labs Q3 2025 presentation: organic growth solid despite market challenges - Investing.com Australia
Earnings call transcript: Abbott Labs Q3 2025 sees stable EPS, stock dips - Investing.com
Abbott revenue misses as diagnostics, nutrition weakness clouds medical devices lift - Reuters
Abbott Laboratories Remains In Favor With London Investment Manager, New Filing Shows - The Motley Fool
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over? - ts2.tech
Medical device business accelerates but diagnostics 'lose momentum'; Abbott Laboratories' performance falls short of expectations. - 富途牛牛
1 No-Brainer Dividend Stock to Buy and Hold Forever - AOL.com
Abbott (ABT) Stock Falls Despite Meeting Earnings Expectations – Here’s Why - parameter.io
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs - TradingView
S&P Health Giant Skids On Mixed Third-Quarter News - Investor's Business Daily
Abbott's earnings forecast dips as a new tariff probe looms - Crain's Chicago Business
Abbott Laboratories posts steady sales growth in Q3, reaffirms full-year guidance - Proactive financial news
ABT Sees Growth from New Products and Biosimilars - GuruFocus
Abbott Cuts Top End of 2025 Guidance as Tariff Threat Looms - Bloomberg.com
Abbott Laboratories reports results for the quarter ended September 30Earnings Summary - TradingView
Here's What Key Metrics Tell Us About Abbott (ABT) Q3 Earnings - Yahoo
Why Is Abbott Laboratories Stock Falling Today?Abbott Laboratories (NYSE:ABT) - Benzinga
Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Abbott Laboratories (ABT) Faces Revenue Shortfall Despite Earnin - GuruFocus
Abbott Laboratories (ABT) Anticipates Earnings Surge - GuruFocus
Stock Market Today: S&P 500, Nasdaq Futures Rise— Bank Of America, Morgan Stanley, Abbott Earnings In Focus (UPDATED) - Benzinga
Abbott Laboratories Revises Annual Earnings Outlook In Line With View; Stock Down In Pre-Market - Nasdaq
Abbott Posts Steady Growth As Medical Devices Shine - Finimize
Earnings Snapshot: Abbott Laboratories Q3 misses revenue estimates; narrows FY profit outlook range - MSN
Abbott in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q3, up 14.8% - MSN
Abbott Laboratories down after Q3 topline miss - MSN
Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. - MSN
Abbott (ABT) Q3 Earnings Meet Estimates - Yahoo
Will Abbott Laboratories (ABT) beat quarterly earnings? - Polymarket
Abbott revenue falls short of estimates on weak demand for diagnostic devices - Yahoo
Abbott Laboratories stock down on Q3 topline miss (ABT:NYSE) - Seeking Alpha
Abbott Reaffirms Earnings Guidance for the Year 2025 - MarketScreener
Abbott misses revenue expectations on weak demand for diagnostic devices - MSN
0.07%
0.14%
자본화:
|
볼륨(24시간):